
<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/cs.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [
		];
		
	</script>
</head>
<body class="slide-1">

<div id="content">
<div class="blueoverlay"></div>

<header>
<strong>CASTLE</strong><br>
KALETRA vs ATV/RTV in ARV-naïve patients

</header>

<div class="headerborder"></div>
<div class="logo"></div>

<section>

<p>International, multicenter, open-label, randomized, 96-week study to determine<br>the comparative clinical efficacy and safety of atazanavir/ritonavir (ATV/RTV) and<br>KALETRA in treatment-naïve HIV-1–infected patients.<sup>2,3</sup></p>
<p><strong>Primary endpoint</strong></p>
<p class="bullet">Proportion of patients with HIV-1 RNA &lt;50 copies/mL at week 48 (ITT-CVR,* NC=F*).</p>
<p class="toppad"><strong>Primary objective</strong></p>
<p class="bullet">Demonstrate non-inferiority of ATV/RTV once daily vs KALETRA twice daily based on primary endpoint if the lower limit of the confidence interval was greater than –10%.</p>
<p><span>*ITT-CVR, intent-to-treat, confirmed virologic response; NC=F, non-completer equals failure.</span></strong></p>


</section>

<div class="buttonwrap">
    <button onclick="makecall('PopupWithHeader',Array('cs-01-popup-01','Study Design','<table width=\'830px\'><tr align=\'center\'><td class=\'reference\'>CASTLE Study Design<sup>2,3</sup></td></tr></table>','90','625','10','0','830','500','1','0','1','0'));">Study Design</button>

</div>

<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>


</div>
</body>
</html>